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health and economic consequences of smoking cessation thera-
pies. The transition probabilities of morbidity and mortality and
the efﬁcacy were taken from published studies. The model allows
cost effectiveness analyses for different time frames (10 years, 20
years and life time). Outcomes are measured in terms of incre-
mental life years gained (LYG) and QALYs. Pharmacological
costs and costs of medical visits for the treatment with vareni-
cline and bupropion were considered. Treatment costs of
smoking associated morbidity were taken from Spanish studies.
Results were expressed in terms of incremental cost per life year
gained and incremental cost per QALY of varenicline versus
comparators. The analyses were done under the perspective of
the National Health System, discounting costs and health ben-
eﬁts at 3 percent. RESULTS: The life time cost-effectiveness
analysis shows that varenicline dominates all other smoking ces-
sation interventions (more effective at a lower cost). This is due
to the higher efﬁcacy of varenicline associated with a reduction in
smoking related morbimortality, which, in the long term,
accounts for health care cost savings that overcome the extra cost
of varenicline. When shorter timeframes are considered, vareni-
cline presents values under 9.000 €/QALY and 50.000 €/QALY
(analyses at 20 and 10 years respectively). CONCLUSION:
Varenicline is a dominant option (more effective at a lower cost)
compared with all other smoking cessation treatments when the
timeframe is the life span of the patient. Varenicline is cost-
effective even when shorter timeframes are considered (20 years
or more), with an estimated incremental cost per QALY well
bellow the threshold commonly accepted in our environment:
30,000 €/QALY.
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OBJECTIVES: To assess the cost-effectiveness of a structured
community pharmacist based smoking cessation (CPS) program
compared with usual care from health care system perspective in
Thailand. METHODS: A Markov model depicting the conse-
quences of smoking was constructed. Health states included
chronic obstructive pulmonary disease, lung cancer, stroke, coro-
nary heart diseases. Cohorts of 10,000 male and female smokers
with age of 40, 50 and 60 years, who smoke regularly 10–20
cigarettes per day, were simulated until death. Transition prob-
abilities were obtained from literature review, while medical care
costs and utilization patterns were derived from electronic
medical database of a Thai tertiary care hospital and literature.
Costs of a structured community pharmacist based smoking
cessation program were obtained from a costing study of 40 Thai
community pharmacies. Incremental cost per life year gained
(LYG) was calculated. The discount rate used was 3%. A series of
sensitivity analyses including probabilistic sensitivity analyses
were also performed. RESULTS: In base-case analysis, the CPS
program results in cost-savings 17,503.53 baht and gains in life
year of 0.181 year for male; costs-savings 21,499.75 baht and
gains in life years of 0.244 year for female. A series of one-way
sensitivity analyses demonstrate that both cost-savings and gain
in life years were very sensitive to change in discount rate and
long term quit rate of smoking cessation interventions. Based on
probabilistic sensitivity analysis, CPS program led to cost-saving
and life year gained in approximately 84% of the simulation.
CONCLUSION: The CPS program results in cost-saving and
gains in life years compared to usual care. This ﬁnding will be
used as a piece of important information for assisting policy
makers in deciding whether resources should be allocated to
smoking cessation service in community pharmacy.
SMOKING—Patient Reported Outcomes
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OBJECTIVES: Varenicline a a4b2 nicotinic achetylcholine recep-
tor partial agonist has been shown to be effective and cost-
effective as a smoking cessation aid when given as a 12-week
treatment course. Recent data suggests incremental quit rates are
seen if further 12 weeks of varenicline treatment are given. This
study was designed to model the cost-effectiveness of this addi-
tional 12 weeks of varenicline treatment compared with other
available courses of existing smoking cessation drug interven-
tions. METHODS: The authors have previously developed a
Markov model, the Beneﬁts of Smoking Cessation on Outcomes
(BENESCO), which estimates the outcomes and costs of a hypo-
thetical population cohort of current US smokers who make a
single attempt to quit smoking. This is a dynamic micro-
simulation model which models the cost-effectiveness of all the
currently available drug-based smoking-cessation modalities
(NRT/bupropion/varenicline) and unaided cessation. In the origi-
nal version of the BENESCO model, subjects were only allowed
to make a one-off attempt to quit. In this updated version of the
model subjects who have successfully quit following an initial 12
weeks of treatment were permitted a second 12-week treatment
course. Results for maintenance therapy with Varenicline were
encorporated into the BENESCO model using a mixed treatment
comparison. RESULTS: Varenicline, 24 weeks, was found to
dominate bupropion, NRT and unaided smoking cessation strat-
egies over the lifetime of the model. CONCLUSION: Varenicline
when given for 12 or 24 weeks is a highly cost effective smoking
cessation aid. The additional 12 weeks of therapy in initial quit-
ters represents excellent value for money for health services
wishing to reduce the numbers of smokers, smoking-related mor-
bidities and deaths in their populations.
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OBJECTIVES: To evaluate the effects of smoking cessation treat-
ment with varenicline in Germany. METHODS: The health-
economic model follows a hypothetical cohort of smokers in
Germany who make a single attempt to quit smoking. The
Markov model considers the possibility of the following
smoking-related diseases: chronic obstructive pulmonary disease
(COPD), coronary heart disease (CHD), stroke and lung cancer.
The time horizon of the model covers the whole lifespan of the
initial cohort with a discount rate of 5% for costs and health
effects. Smoking cessation with varenicline will be compared
with bupropion, nicotine replacement therapy (NRT) and
unaided cessation (status quo) from the health care system per-
spective. RESULTS: Based on the demographic data used, the
model baseline cohort consists of 5.18 million smokers. On the
basis of the results of this study, smoking cessation with vareni-
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cline proved cost-saving or cost effective in relation to the alter-
natives studied. Overall, a gain of about 78–200 thousand life
years (LYG) or 88–226 thousand quality-adjusted life years
(QALYs) can be obtained in a long-term. The incremental cost-
effectiveness ratio (ICER) is 2.330 EUR per LYG (2.073 per
QALY) and 1.781 EUR per LYG (1584 per QALY) compared to
unaided cessation or bupropion, respectively. Varenicline is a
dominant strategy compared to NRT. Even if the savings from
avoided smoking-related diseases are ignored and the time
horizon will be reduced to 20 years, varenicline remains cost-
effective with ICER under 18.000 EUR per LYG and QALY
compared to all other alternatives. CONCLUSION: The results
corroborate the ﬁndings of health beneﬁts and favourable cost-
effectiveness of smoking cessation pharmacotherapy from former
studies.
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OBJECTIVES: Prior to use in an international study, the Insulin
Treatment Satisfaction Questionnaire (ITSQ) and the Environ-
mental Tobacco Smoke Questionnaire (ETS-Q) underwent lin-
guistic validation in 10 and 6 languages respectively. The original
scales containing 22 and 3 items were developed in US and UK
English respectively. Rigorous methodology was required to
ensure conceptual equivalence and cultural relevance across dif-
ferent languages. METHODS: The translation process was con-
ducted by a specialist in each target country using the following
standardized methodology: 1) two forward translations by pro-
fessional translators; 2) comparison and reconciliation of the
translations by the specialist in the target country; 3) backward
translation; 4) comparison of source and backward version; 5)
review by a clinician (for the ITSQ only); and 6) comprehension
test on a small sample of the target population diagnosed with
diabetes and undergoing insulin treatment (for the ITSQ only).
RESULTS: Linguistic and conceptual issues emerged during the
translation process. Firstly, when an original item used two adjec-
tives to cover one concept some languages only had one term to
express this. Secondly, some concepts, in particular in relation to
meals, do not exist in certain Indian languages and paraphrases
had to be found to ensure conceptual equivalence with the origi-
nal and appropriateness in the target language. CONCLUSION:
The language versions of the ITSQ and the ETS-Q were estab-
lished according to rigorous translation methodology. The
process aims to ensure conceptual equivalence across different
language versions to facilitate international comparison and
pooling of data. Thus, the result is linguistically validated ques-
tionnaires. The linguistic validation process as a whole supports
the advantage of integrating international feedback on concepts
and wording before a questionnaire is ﬁnalized.
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REAL WORLD USAGE PATTERNS OF OVER-THE-COUNTER
NICOTINE PATCHES
Shi CW, Ganiats T
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OBJECTIVES: Little is known about how the public uses the
nicotine patch after it was reclassiﬁed from prescription to over-
the-counter (OTC) status. This observational study describes the
characteristics of consumers who purchase OTC nicotine patches
from pharmacies and to determine factors associated with off-
label use of nicotine patch. METHODS: Prospective, longitudi-
nal study of N = 600 OTC nicotine patch consumers from a
random sample of 30 retail pharmacies throughout San Diego
County. Each subject completed a self-administered, anonymous
questionnaire at the time of purchase and at 2-weeks after using
the patch. Off-label use was deﬁned as intention to smoke while
on the patch or using the patch for harm reduction rather than
quitting. Logistic regression was performed to determine the
factors associated with off-label use. RESULTS: The cohort had
low Fagerstrom nicotine dependence score (mean = 3.58). Sixty-
four percent stated that their physicians were not aware of them
using the patch. Main reasons prompting purchase included self-
initiative (54%), family/friends (20%), physician advice (15%),
and pharmacist’s advice (3%). Eight percent intend to use the
patch for harm reduction rather than quitting. Minorities and
individuals with high income were more likely to engage in
off-label use. Of those who returned the second questionnaire
(N = 155), 78% did not review the self-aid counseling materials
enclosed in the product package. Forty-ﬁve percent reported
smoking cigarettes at 2 weeks, and 8% admitted to using more
than one patch per day. CONCLUSION: A substantial number
of the consumers had low Fagerstrom nicotine dependence scores
and would not have qualiﬁed as for the patch under the prescrip-
tion setting. Most consumers did not review the self-aid materials
even though it was included in the package, and some consumers
intentionally engaged in off-label use of the product. Further
research is needed to devise interventions to ensure proper usage
of OTC nicotine patch by the public.
SURGERY—Cost Studies
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COST-EFFECTIVENESS OF STAPLED HAEMORRHOIDOPEXY
(PPH) COMPARED WITH MILLIGAN-MORGANTECHNIQUE
MM IN PATIENTS IN WHOM SURGICAL INTERVENTION IS
CONSIDERED APPROPRIATE FORTHETREATMENT OF
PROLAPSED INTERNAL HAEMORRHOIDS IN
UNITED KINGDOM
Grifﬁn A1, Rupprech F2, Ribaric G2, Morlotti L2
1Johnson & Johnson, Bucks, UK, 2Ethicon Endo Surgery, Norderstedt,
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OBJECTIVES: To evaluate the cost-effectiveness of PPH com-
pared to MM for treating prolapsed internal haemorrhoids from
the NHS’s perspective. METHODS: A cohort-based model with
a decision tree structure was developed to investigate the cost
effectiveness of PPH in the treatment of haemorrhoids; the
primary outcome was total direct NHS cost and QALYs. Patients
in whom surgical intervention is considered appropriate enter the
model having undergone either a PPH or MM procedure. The
patient then goes through a recovery period during which a
proportion of the patients may suffer a recurrent prolapse. The
severity of the recurrent prolapse determines whether the patient
is able to self-treat or requires further surgery. Those who require
re-surgery are readmitted to hospital and undergo the same pro-
cedure they had on entry to the model. Resource utilisation
associated with procedure cost and post operative complication
was estimated by NHS reference costs 2006. RESULTS: Cost
drivers were identiﬁed as the cost of the stapling device and
reductions in length of stay in the PPH group. QALYs were
driven by reductions in post-operative pain from PPH. Total
direct NHS costs per were 972.66 and 928.66 for PPH and
MM, respectively. PPH vs. MM offers a cost saving of 10.74/
patient due to less length of stay and OR time considering the
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